Stacie Weninger is the Executive Director of the F-Prime Biomedical Research Initiative. Prior to this position, she was the Senior Director of Science Programs for the Fidelity Foundations. In 2005, Dr. Weninger served as the Project Manager and Senior Analyst for the Task Force on Women in Science at Harvard University. From 2001-2005, she was a Senior Scientist at Cell Press for the journal Neuron. Before joining Cell Press, Dr. Weninger was a postdoctoral research fellow at Children's Hospital Boston and Harvard Medical School with Dr. Bruce Yankner. She was a Howard Hughes Medical Institute predoctoral fellow in the Program in Neuroscience at Harvard University. While a graduate student and postdoctoral research fellow, Dr. Weninger was actively involved in undergraduate teaching, winning six teaching awards.
Dr. Weninger received a Ph.D. in neuroscience from Harvard University, and a B.S. degree in chemistry with highest honors from the University of North Carolina at Chapel Hill. She currently chairs the Collaboration for Alzheimer's Prevention; is President of Alzforum; serves as Chairman of the Board of Directors for Rugen Therapeutics; and serves as a member of the Board of Directors for Zebra Medical Technologies, Aratome, Inscopix, BRI-Alzan, BRI-Tolan, Q-State Biosciences, and Denali Therapeutics. She previously served as a member of the Board of Directors for Annexon Biosciences.